Merck is investing 300 million euros, or about $338 million, in a new production facility in Daejeon as the German science and technology company expands its presence in Asia. Merck described the project as its largest life-science investment in the Asia-Pacific region.
- Investment
- 300 million euros, or about $338 million
- Location
- Daejeon, South Korea
- Strategic purpose
- Serve Asian demand while reducing reliance on US and European production sites
The company said the Daejeon site will help reduce reliance on production centers in the United States and Europe while allowing it to respond to Asian customer demand from within the region. Merck’s life-science chief said research and development activity in Asia, including South Korea and Japan, is growing at a double-digit pace, while the region’s share of the global innovation pipeline has risen from 28% in 2020 to more than 40%.
Merck cited South Korea’s biomanufacturing capabilities and highly educated workforce as key reasons for selecting the site. The company also linked the decision to supply-chain lessons from the pandemic, when demand surged before falling sharply. It said artificial intelligence and data analysis will be important for detecting unusual demand early and improving forecasting, although the company did not provide employment figures or a production timetable for the Daejeon facility.
